Streetbeat News

Stock Prices

NXU

Trading for NXU was halted and then resumed at 8:55 AM ET, with updated status including news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:55 pm

PINS

Wedbush analyst Scott Devitt has maintained a Neutral rating on Pinterest (NYSE:PINS) but increased the price target from $32 to $35.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:53 pm

AAPL

Apple Inc (NASDAQ:AAPL) shares closed slightly lower on Tuesday. The company is exploring licensing its content to news and publishing firms and is under DOJ scrutiny for blocking the Beeper app. Apple's dividend yield is 0.50%, with a quarterly dividend of 24 cents per share. To earn $500 monthly from dividends, one would need to own 6,250 shares, valued at approximately $1,206,563. The dividend yield fluctuates with stock price and dividend changes. AAPL shares fell 0.3% to close at $193.05.

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 1:52 pm

BWEN

MKTX

Broadwind Inc (BWEN) has agreed to sell approximately $15 million of Advanced Manufacturing Production Credits to MarketAxess Holdings, Inc. (MKTX) under the Inflation Reduction Act. The tax credits are related to Broadwind's domestic production and sale of wind turbine components. Broadwind will also sell section 45X tax credits generated in 2024 on a quarterly basis. CEO Eric Blashford highlighted the economic incentive for renewable energy investment provided by the 45X tax credit. BWEN's stock saw a slight increase of 0.35% in premarket trading.

Portfolio Pulse from Shivani Kumaresan

December 27, 2023 | 1:52 pm

META

Wedbush analyst Scott Devitt has maintained an Outperform rating on Meta Platforms (NASDAQ:META) and increased the price target from $350 to $420, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:51 pm

MELI

Wedbush analyst Scott Devitt has maintained an Outperform rating on MercadoLibre (NASDAQ:MELI) and increased the price target from $1700 to $1800.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:48 pm

CHRS

Coherus BioSciences' stock is trading higher following the announcement of FDA approval for UDENYCA ONBODY, a pegfilgrastim-cbqv product.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:46 pm

FWBI

First Wave BioPharma's stock price has risen following the announcement of a non-binding term sheet to sell its Niclosamide program, which is aimed at treating inflammatory bowel diseases.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:44 pm

FWBI

SNY

First Wave BioPharma, Inc. (FWBI) shares surged after announcing a non-binding term sheet to sell its Niclosamide program for IBD treatment to an undisclosed biopharmaceutical company. The deal includes a low seven-figure upfront payment, future milestones, and royalties. This allows FWBI to concentrate on its late-stage clinical programs, including those licensed from Sanofi (SNY). The transaction is expected to close in the first half of 2024, and FWBI shares rose 143% premarket.

Portfolio Pulse from Nabaparna Bhattacharya

December 27, 2023 | 1:40 pm

FUSN

Fusion Pharmaceuticals' stock (FUSN) has been upgraded by Raymond James from Outperform to Strong Buy, with an increased price target from $12 to $15, leading to higher trading of the shares.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:40 pm